These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 21128693)
1. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. Gold R CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693 [TBL] [Abstract][Full Text] [Related]
13. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. English C; Aloi JJ Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574 [TBL] [Abstract][Full Text] [Related]
15. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis. Kretzschmar B; Pellkofer H; Weber MS Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956 [TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Guarnera C; Bramanti P; Mazzon E Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828 [TBL] [Abstract][Full Text] [Related]
17. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Sørensen PS J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763 [TBL] [Abstract][Full Text] [Related]
18. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. di Nuzzo L; Orlando R; Nasca C; Nicoletti F Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766 [TBL] [Abstract][Full Text] [Related]